Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Canopy Growth Corp (CGC) vs Stryker Corporation (SYK) Price & Performance

Canopy Growth CorpTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Canopy Growth Corp vs Stryker Corporation — how do they compare? Canopy Growth Corp trades at $0.96 (market cap $398.46M), while Stryker Corporation trades at $311.21 (market cap $119.25B). The key difference: Stryker Corporation is far larger — about 299.3× Canopy Growth Corp's market cap, and Stryker Corporation pays a 1.13% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.

CGCSYK
Market Cap
$398.46M$119.25B
Sector
HealthTechnology
52-Week High
$1.92$403.53
52-Week Low
$0.86$282.58
Enterprise Value
$337.90M$131.01B
Dividend Yield
1.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Canopy Growth Corp

Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.

The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.

Stryker Corporation

Stryker (SYK) trades at $331.45, up 0.51% today, with strong analyst support (74% buy ratings) and a consensus price target of $388.44. The stock shows bullish technical signals despite a recent Q1 2026 earnings miss attributed to a temporary cyber disruption. Fundamentals remain solid with 2025 revenue of $25.12B, net income margin of 13.21%, and robust cash flow generation of $5.04B from operations.

Outlook remains positive with maintained full-year guidance and healthy end-market demand. Investment opportunity lies in the valuation discount to historical averages and innovation-driven growth. Key risks include cybersecurity vulnerabilities and competitive pressures in the medtech sector. The stock offers potential upside of 17% to consensus target with dividend stability as a Dividend Aristocrat.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Canopy Growth Corp

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.

Read more on CGC

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK